DFTX Definium Therapeutics, Inc.

NASDAQ
$30.16

Definium Therapeutics, Inc. (DFTX) is expected to report earnings on February 8, 2027, after the market close. The consensus earnings estimate is a loss of $0.51 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -12.5% since its last earnings release on November 9, 2026.

Definium Therapeutics Beat Consensus Estimates
Monday, November 9, 2026 · 4:01 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 8
Monday · 4:00 PM ET
Earnings Whisper
-
vs ($0.51)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $33.05

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Definium Therapeutics, Inc.

Definium Therapeutics, Inc. is developing therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Definium Therapeutics Inc., formerly known as Mind Medicine Inc., is based in NEW YORK.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.